AdCom Approval, Reservations on Praluent Largely Inline with Expectations; Roth Affirms Regeneron (REGN) at 'Neutral'
Tweet Send to a Friend
Roth capital affirms Regeneron Pharmaceuticals (Nasdaq: REGN) with a Neutral rating and $495 price target after the company confirmed that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
